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Macrophage migration inhibitory factor (MIF) has been defined as an important chemokine-
like function (CLF) chemokine with an essential role in monocyte recruitment and arrest.
Adhesion of monocytes to the vessel wall and their transendothelial migration are critical
in atherogenesis and many other inflammatory diseases. Chemokines carefully control all
steps of the monocyte recruitment process. Those chemokines specialized in controlling
arrest are typically immobilized on the endothelial surface, mediating the arrest of rolling
monocytes by chemokine receptor-triggered pathways. The chemokine receptor CXCR2
functions as an important arrest receptor on monocytes. An arrest function has been
revealed for the bona fide CXCR2 ligands CXCL1 and CXCL8, but genetic studies also sug-
gested that additional arrest chemokines are likely to be involved in atherogenic leukocyte
recruitment.While CXCR2 is known to interact with numerous CXC chemokine ligands, the
CLF chemokine MIF, which structurally does not belong to the CXC chemokine sub-family,
was surprisingly identified as a non-cognate ligand of CXCR2, responsible for critical arrest
functions during the atherogenic process. MIF was originally identified as macrophage
migration inhibitory factor (this function being eponymous), but is now known as a potent
inflammatory cytokine with CLFs including chemotaxis and leukocyte arrest. This review
will cover the mechanisms underlying these functions, including MIF’s effects on LFA1
integrin activity and signal transduction, and will discuss the structural similarities between
MIF and the bona fide CXCR2 ligand CXCL8 while emphasizing the structural differences.
As MIF also interacts with CXCR4, a chemokine receptor implicated in CXCL12-elicited
lymphocyte arrest, the arrest potential of the MIF/CXCR4 axis will also be scrutinized as
well as the recently identified role of pericyte MIF in attracting leukocytes exiting through
venules as part of the pericyte “motility instruction program.”
Keywords: chemokine, leukocyte recruitment, arrest, signal transduction, atherosclerosis, inflammation
INTRODUCTION
Leukocyte recruitment and arrest are central steps in inflam-
matory reactions and associated diseases, including atheroscle-
rosis (Box 1). Identifying the main players mediating chemotaxis
and arrest is therefore crucial. Boisvert et al. (1998) revealed an
important role for the chemokine receptor CXCR2 in mediating
monocyte recruitment into atherosclerotic lesions by showing a
reduced lesion size and macrophage content in atherosclerosis-
prone Ldlr−/− mice transplanted with Cxcr2-deficient bone mar-
row. Although mice do not express an ortholog of the CXCL8/IL8
ligand of human CXCR2, the Cxcr2 ligand Cxcl1 (also known
as KC/Gro-α) was detected in advanced lesions in mice (Boisvert
et al., 1998)1. However, a subsequent study in 2006 showed that
the reduction in lesion size in Cxcl1-deficient Ldlr−/− mice didn’t
1Throughout the manuscript, the letter format of all gene and protein notations
was chosen to conform with internationally agreed gene/protein nomenclature
guidelines: all letters of human genes/proteins are in uppercase, whereas for mouse
genes/proteins, only the first letter is in uppercase and the remaining letters are in
lowercase. Gene names are in italics.
exceed half of what was observed in the bone marrow-specific
Cxcr2 knock-out (Boisvert et al., 2006), suggesting the presence
of other relevant Cxcr2 ligands with an important role in mono-
cyte recruitment during atherogenesis. In fact, one such factor
was uncovered a year later and was found to be the inflammatory
cytokine macrophage migration inhibitory factor (MIF). MIF was
originally discovered half a century ago as a T-cell-derived factor
inhibiting the random migration of macrophages out of capil-
lary tubes and thus was termed macrophage migration inhibitory
factor. However, following its cloning and the biochemical char-
acterization and preparation of MIF protein, MIF was later on
redefined to be a pleiotropic inflammatory cytokine with critical
roles in physiological immunity but also inflammatory diseases
and cancer (Bernhagen et al., 1993; Calandra and Roger, 2003).
Although the migration inhibitory activity of MIF was not stud-
ied and characterized much further, the eponymous name “MIF”
was kept up over the years. It was thus largely unexpected, when
MIF was identified as a ligand of CXCR2, exhibiting chemokine-
like properties, and shown to be a crucial pro-atherogenic factor
(Bernhagen et al., 2007). Intriguingly, MIF/CXCR2 interaction
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Box 1 The leukocyte adhesion cascade.
Leukocyte arrest on inflamed endothelium can be divided into three main steps: rolling, adhesion, and transmigration. Leukocyte rolling is
mediated by the binding of leukocyte-derived PSGL1 to the selectins P-selectin and E-selectin on inflamed endothelial cells (ECs). Next,
chemokines triggering their respective G protein-coupled receptor (GPCR) on the leukocyte cell surface promote leukocyte integrin activation,
resulting in leukocyte arrest. Finally, leukocytes transmigrate across the endothelium into the vessel wall, which can occur by paracellular
(through endothelial junctions) or transcellular route (through the EC body). This three-step model has been refined over the last years, to
include tethering (capture), rolling, slow rolling, arrest, adhesion strengthening, intraluminal crawling, and transmigration (Ley et al., 2007).
was found to trigger the recruitment and arrest of monocytes,
whereas MIF-mediated T-cell recruitment could be traced to an
interaction of MIF and yet another chemokine receptor. This was
CXCR4, a CXC chemokine receptor thought to be much more
specific regarding its ligand spectrum than CXCR2 (Bernhagen
et al., 2007). Interestingly, MIF-mediated monocyte recruitment
had previously been described in other inflammatory diseases,
such as arthritis and glomerulonephritis (Lan et al., 1997; Morand
et al., 2006), but was thought to represent an indirect event at
the time. And although the third MIF receptor CD74 was already
identified as a MIF-interacting membrane protein in 2003, a direct
role of CD74 in MIF-mediated monocyte chemotaxis and arrest
was not revealed until the discovery of CXCR2/CD74 complexes
in 2007. Interestingly, it is now also clear that CD74 has a role in
atherogenesis (Sun et al., 2010).
This review discusses MIF’s role as a chemokine-like mediator,
addressing its structure, receptor binding capacity and impor-
tance in leukocyte recruitment, particularly arrest, in the context
of atherosclerosis.
MIF AS AN IMPORTANT CHEMOKINE-LIKE
FUNCTION – CHEMOKINE
Chemokines are 8–12 kDa cytokines with chemotactic properties,
playing a fundamental role in leukocyte trafficking (Bajetto et al.,
2002; Weber et al., 2004; Charo and Ransohoff, 2006). Typically,
a chemokine consists of a disordered N-terminus containing a
characteristic cysteine motif, an N-loop region, three antiparallel
β-strands linked by turns designated 30s-, 40s-, and 50s-loop, and
a C-terminal α-helix, which together form the typical chemokine
fold (Clark-Lewis et al., 1995). Chemokines share 20–50% gene
and amino acid homology, and are classified into four groups
depending on the presence and spacing of their N-terminal cys-
teine residues. These groups comprise the C, CC, CXC, and
CXXXC chemokines, with the CXC and CC groups being most
prominent (Murphy et al., 2000). The N-terminal cysteine motif
stabilizes the chemokine structure by forming two disulfide bonds,
one between the first cysteine with a cysteine in the 30s-loop, and
the other one between the second cysteine and a cysteine in the 50s-
loop (Fernandez and Lolis, 2002). Chemokines exert their specific
function by binding to rhodopsin-like G protein-coupled recep-
tors (GPCRs), which contain a seven-transmembrane domain and
signal through heterotrimeric G proteins (Thelen and Didichenko,
1997; Murphy et al., 2000; Thelen, 2001; Bajetto et al., 2002; Charo
and Ransohoff, 2006). The receptors are classified according to
the chemokines they bind (Murphy et al., 2000). It has been sug-
gested that for all chemokine sub-groups, the binding mechanism
follows a so-called two-site-binding mechanism. First, there is
an interaction between the N-loop of the chemokine with the
N-terminus of the receptor (site I interaction). This results in
a conformational change of the receptor and allows a second
interaction between the N-terminus of the chemokine and the
extracellular loops of the receptor (site II interaction) (Clark-Lewis
et al., 1995; Rajagopalan and Rajarathnam, 2006).
In the last decade, there was a raising need to establish an addi-
tional chemokine category, to accomodate proteins that exhibit
similar functions as the prototypical, “classical” chemokines, but
that lack the typical chemokine structure. Characteristics of this
group of “chemokine-like function (CLF) – chemokines” were
defined as follows: (i) CLF chemokines are released during infec-
tion, inflammation, or cell stress by non-classical export or due
to cell death; (ii) they do not usually share the typical chemokine
fold and the N-terminal residues with the classical chemokines;
(iii) they exhibit chemokine-like activities in particular promoting
chemotaxis; and (iv) they typically interact with a GPCR, preferen-
tially functioning as non-cognate ligand of a classical chemokine
receptor (Degryse and de Virgilio, 2003; Yang et al., 2004; Oppen-
heim and Yang, 2005; Noels et al., 2009). Some representatives of
this sub-group and their characteristic features are listed in Table 1.
MIF is a typical CLF chemokine, as missing cysteines in its
N-terminus do not allow for a classification of MIF into one of
the four prototypical chemokine classes, although MIF shares sev-
eral features with chemokines (Box 2). As such, MIF mediates the
recruitment of monocytes, T-cells, neutrophils, endothelial prog-
enitor cells, and tumor cells (Ren et al., 2003; Gregory et al., 2006;
Bernhagen et al., 2007; Takahashi et al., 2009; Brandau et al., 2010;
Dessein et al., 2010; Simons et al., 2011). Furthermore, MIF is
immobilized on the endothelial cell (EC) surface (Schober et al.,
2004; Bernhagen et al., 2007), where it induces leukocyte arrest
(Schober et al., 2004; Amin et al., 2006). Interestingly, MIF was
shown to directly mediate these chemokine-like functions by trig-
gering the activation of leukocytic integrins (Box 3) through
the CXC chemokine receptors CXCR2 and CXCR4 on mono-
cytes/neutrophils and T-cells, respectively (Bernhagen et al., 2007;
Zernecke et al., 2008; Kraemer et al., 2012)¸ as discussed in more
detail below.
In addition, MIF indirectly enhances leukocyte arrest by
inducing the expression of adhesion molecules or other
chemokines. This has been observed for both endogenous and
exogenous MIF on ECs and leukocytes, either by MIF stimulation
alone, or by MIF in combination with other pro-inflammatory
stimuli. For example, Mif-deficient mice show a reduced adhesion
of leukocytes to the endothelium of the cremaster microvascu-
lature upon injection of inflammatory agents such as Tnfα and
lipopolysaccharide (LPS), or chemokines such as Cxcl1 or Ccl2
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Box 2 Macrophage migration inhibitory factor (MIF).
Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine with chemokine-like functions, thus placing it into the
CLF chemokine class. The sequence of MIF differs by only one residue from a protein mediator called glycosylation-inhibiting factor (GIF).
The name “macrophage migration inhibitory factor” goes back to the initial discovery of MIF in 1966, when MIF-containing T-cell super-
natants were found to inhibit the random migration of guinea pig macrophages out of capillary tubes (David, 1966). As a CLF chemokine,
MIF acts as a chemoattractant for leukocytes, endothelial progenitor cells, and certain tumor cells, and mediates many pro-inflammatory
processes through the induction of cytokines, chemokines, and adhesion molecules. Also, MIF counteracts the anti-inflammatory activity
of glucocorticoids. MIF has been implicated in a variety of acute and chronic inflammatory diseases like sepsis, atherosclerosis, rheumatoid
arthritis, inflammatory lung disease, or systemic lupus erythematosus. MIF also is a tumor promoter in most models (Calandra and Roger,
2003). MIF signals through its high affinity receptor CD74, a surface form of the MHC class II invariant chain Ii, and through the chemokine
receptors CXCR2 and CXCR4. Apart from CLF functions, MIF exhibits evolutionarily conserved catalytic activities as an oxidoreductase and
tautomerase activity.The physiological and pathophysiological relevance of these catalytic functions, which can readily be detected in vitro,
is still unclear (Kraemer et al., 2012). The tautomerase activity of MIF is shared by D-dopachrome tautomerase (D-DT), a protein with 34%
amino acid homology to MIF in humans, and 27% in mice. D-DT also binds to CD74 and has a broad overlapping spectrum of functions and
therefore was recently designated as MIF-2 (Merk et al., 2012). Unfortunately, MIF is frequently mixed up with another chemokine with a
similar name, i.e., macrophage inflammatory protein-1α (MIP-1α or CCL3). This chemokine also acts in a pro-inflammatory manner and is
produced and secreted by macrophages, but unlike MIF, MIP-1α is classified into the CC chemokine class and is formally not related to MIF
by structure.
Box 3 Integrins.
Integrins are αβ heterodimeric transmembrane proteins mediating the arrest of cells to the extracellular matrix (ECM) or other cells through
interaction with ECM proteins (e.g., fibronectin, laminin, collagen, and vitronectin) or integrin ligands (e.g., VCAM1, ICAM1), respectively.
Currently, 19α and 8β subunits have been identified in vertebrates, which can be assembled into 24 different integrins. Well-studied are the
β1-integrin VLA4 (α4β1) and the β2-integrins LFA1 (αLβ2, CD11a/CD18) and MAC1 (αMβ2, CD11b/CD18), which bind to VCAM1 and ICAM1,
respectively (Zhang and Wang, 2012). The association strength between a specific integrin heterodimer and a ligand is called “integrin
affinity.” It is dependent on the composition and conformation of the integrin, the latter being modulated by intracellular signaling events
triggered by, e.g., GPCR stimulation. For LFA1, at least 3 different conformations have been demonstrated. In its “closed,” inactive state,
the extracellular domain of LFA1 is bent towards the plasma membrane, with the ligand-binding headpiece situated close to the membrane,
preventing ligand binding. An intermediate affinity of LFA1 has been linked to an “intermediate extended” state with a closed ligand-binding
headpiece extending above the plasma membrane. The high affinity, “open” conformation of LFA1 is coupled to the “opening” of the
ligand-binding headpiece through conformational rearrangements. This “open headpiece” of LFA1 has been shown to be necessary and
sufficient for cell arrest under flow (Lefort and Ley, 2012).
Besides integrin affinity, cellular adhesion strength is affected by the integrin density, or valency, on the cell surface. This is regulated by
integrin expression and clustering, and contributes to the joined, synergistic strength of all integrin-ligand interactions, called “integrin
avidity” or “functional affinity.” In addition to intracellular signaling cascades regulating integrin affinity (called “inside-out signaling”), ligand
binding by integrins also mediates “outside-in signaling” affecting cellular processes, as for example gene expression, cell proliferation and
survival.
(Gregory et al., 2004; Fan et al., 2011; Santos et al., 2011). For
TNFα, this could be linked to a reduced basal and TNFα-triggered
expression of the integrin ligands VCAM1 and ICAM1, and of the
cytokines IL6, CXCL8, and CCL2 in MIF-deficient ECs, possibly
through a reduced TNFα-induced p38 activation in the absence of
MIF (Cheng et al., 2010). Similarly, the cremaster muscle microvas-
culature of Mif-deficient mice showed a diminished LPS-induced
Vcam1 expression pattern (Gregory et al., 2009). Also, Cxcl1-
induced chemotaxis was significantly reduced in Mif-deficient
neutrophils and was associated with a reduced mitogen-activated
protein kinase (Mapk) activation (Santos et al., 2011). Similarly,
Ccl2-triggered monocyte chemotaxis was severely decreased in the
absence of endogenous Mif. This was associated with a reduced
Rho GTPase and Mapk activation, and a reduced expression of
the α4 integrin and of the Mapk-regulating protein Mkp1 in
Mif-deficient macrophages (Fan et al., 2011). Likewise, exogenous
MIF has been linked to an enhanced expression of chemokines
and adhesion molecules. For example, injection of mice with
recombinant MIF increased monocyte adhesion and endothelial
transmigration in the microvasculature (Gregory et al., 2006; Fan
et al., 2011). This was mostly dependent on Cd74 (Fan et al., 2011)
and associated with enhanced Ccl2 secretion from microvascu-
lar ECs in vitro, without affecting endothelial Vcam1 expression
in vivo (Gregory et al., 2006). In contrast, exogenous MIF upreg-
ulated ICAM1 on a human EC line in vitro (Lin et al., 2000) and
reduced Icam1 expression was seen in the atherosclerotic aorta
of mice treated with a Mif blocking antibody (Burger-Kentischer
et al., 2006). These observations seem to be dependent on the
vascular bed from which the ECs derive, as in contrast to the MIF-
induced arrest responses on microvascular ECs, exogenous MIF
could not induce leukocyte rolling or arrest on HUVECs. How-
ever, TNFα-induced leukocyte rolling and adhesion on HUVECs
were enhanced by exogenous MIF, which could be linked with
an increase in endothelial P-selectin expression, while the TNFα-
induced expression of E-selectin, VCAM1, and ICAM1, or of
different chemokines were unaltered in the presence of exogenous
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MIF (Cheng et al., 2010). Furthermore, MIF mediates neutrophil
accumulation in MIF-triggered lung inflammation by inducing
the chemokines Cxcl1 and Cxcl2/Mip2 in alveolar macrophages
through Cd74/extracellular signal regulated kinase (Erk) signaling
(Takahashi et al., 2009) and can promote neutrophil chemotaxis
in particular in the presence of actively expressed surface CD74
(Bernhagen et al., 2007). In addition, MIF has been shown to
increase the surface expression of ICAM1 and VCAM1 on human
monocytes via PI3K/AKT, p38, and NF-κB (Amin et al., 2006),
which can be shed to soluble adhesion molecules, capable of
mediating leukocyte chemotaxis (Kitani et al., 1998; Tokuhira
et al., 2000). In conclusion, MIF is a pivotal mediator of leuko-
cyte chemotaxis and arrest, by both direct mechanism or through
the induction of other chemokines or adhesion molecules.
In addition to its chemotactic and arrest properties, MIF exerts
pro-inflammatory and anti-apoptotic functions, either through
receptor activation by extracellular MIF (as described in more
detail below) or through intracellular interactions, e.g., with
JAB1/CSN5 or with the pro-apoptotic proteins BIM and p53
(Kleemann et al., 2000; Jung et al., 2008; Liu et al., 2008; Noels et al.,
2009). Furthermore, comparable to other CLF chemokines, MIF
is secreted upon diverse inflammatory or stress factors (Table 2).
This secretion occurs through a non-classical pathway, a so-called
export pathway, as MIF lacks a typical N-terminal consensus secre-
tion sequence required for classical endoplasmic reticulum/Golgi-
mediated protein secretion (Flieger et al., 2003). Of note, MIF
secretion is not only observed in immune cells, but other cell types
with a prominent role in atherogenesis including ECs and SMCs
can also be triggered to secrete MIF (Bernhagen et al., 1994; Noels
et al., 2012).
STRUCTURE – FUNCTION RELATIONSHIPS OF MIF AS A
CXCR2 LIGAND
MIF is a conserved protein, ubiquitously expressed in mammals.
Furthermore, MIF homologs have been identified in avians, fish,
plants (Arabidopsis thaliana), the nematode Caenorhabditis ele-
gans, cyanobacteria, ticks, and parasites, amongst others (Calandra
and Roger, 2003; Kim et al., 2010). The human and mouse MIF
protein consist of 114 amino acids (excluding an N-terminal
methionine, which is processed after ribosomal synthesis), with
a total molecular weight of 12.3 kDa. The human and mouse
orthologs share a 90% sequence homology and lack a conventional
leader sequence targeting proteins for classical secretion (Bern-
hagen et al., 1994). In addition to cytokine and chemokine-like
activities, MIF is unusual in featuring two evolutionarily conserved
catalytic activities, being an oxidoreductase and a tautomerase
activity. Despite its consensus Cys-Xaa-Xaa-Cys motif, structural
similarities between MIF and oxidoreductases such as thiore-
doxin or glutaredoxin are of remote nature only. In contrast, MIF
possesses three-dimensional structural homology with the bacter-
ial isomerases 4-oxalocrotonate-tautomerase, 5-carboxymethyl-2-
hydroxymuconate isomerase, and chorismate mutase (Rosengren
et al., 1997; Kleemann et al., 1998; Calandra and Roger, 2003).
Furthermore, MIF’s overall architecture resembles that of human
D-dopachrome tautomerase (D-DT). Also, MIF and D-DT share
overlapping biological functions, both bind the CD74 receptor,
and activate similar signaling pathways (Sugimoto et al., 1999;
Merk et al., 2012). Therefore, “MIF-2” was recently suggested as
an alternative name for D-DT (Merk et al., 2012). Remarkably, a
MIF ortholog can even be found in the hookworm Ancylostoma
ceylanicum (aceMIF), sharing 28–35% sequence homology with
human MIF. Like the human ortholog, aceMIF shows tautomerase
activity, binds to CD74 and has chemoattractant properties (Cho
et al., 2010). Although the global topology is similar to human
MIF, protein surface and electrostatic potential are distinct (Cho
et al., 2007).
The MIF monomer consists of two antiparallel α-helices and
a four-stranded β-sheet (excluding two really short β-strands), as
displayed in Figure 1. Although MIF has no sequence homology to
other chemokines, the 3D structure of the MIF monomer resem-
bles the dimeric form of CXCL8 and other CXC chemokines
(Weber et al., 2008) (Figure 1). But, the monomer is not the
only existing form of the MIF protein. Nuclear magnetic res-
onance (NMR) analysis suggested that MIF dimerizes, whereas
Table 2 | MIF expression and secretion in cell types relevant in atherogenesis.
Cell type Basal expression MIF expression (secretion) upregulated by Reference
Monocytes/macrophages Yes LPS, TNFα, IFNγ, CD40L, ATII, oxLDL,
bacterial exotoxins, hypoxia, glucocorticoids
Calandra et al. (1994), Schmeisser et al. (2005),
Burger-Kentischer et al. (2002), Calandra et al. (1998),
Schmeisser et al. (2005), Calandra et al. (1995)
T-cells Low T-cell activation (αCD3, PMA/ionomycin)
glucocorticoids
Bloom and Bennett (1966), Bacher et al. (1996),
Bacher et al. (1996)
B-cells Yes Tumor stress signals Wymann et al. (1999), Reinart et al. (2013)
ECs Low LPS, oxLDL, hypoxia, thrombin Nishihira et al. (1998), Burger-Kentischer et al. (2002),
Schober et al. (2004), Schmeisser et al. (2005), Simons
et al. (2011), Zhang et al. (2012), Shimizu et al. (2004)
SMCs Low oxLDL, hypoxia Chen et al. (2009), Zhang et al. (2012)
LPS, lipopolysaccharide;TNF, tumor necrosis factor; IFN, interferon; ATII, angiotensin II; oxLDL, oxidized low density lipoprotein; ECs, endothelial cells; SMCs, smooth
muscle cells.
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FIGURE 1 | Sequence and structure comparison of human MIF and
the cognate CXCR2 ligand CXCL8. (A) Amino acid (aa) sequence
comparison of MIF and CXCL8. (B,C) Comparison of the crystal structure
of the MIF monomer, CXCL8 monomer, CXCL8 dimer, and MIF trimer. To
(A,B): CXCL8 (aa 28–99) is the predominant form of CXCL8. α-Helices
and β-sheets are indicated. Important amino acids and motifs are
highlighted: ELR or pseudo-(E)LR (red); N-loop (for CXCL8) or N-like loop
(for MIF; orange); CALC motif, forming the catalytic center of MIF’s
oxidoreductase activity (blue). The MIF structural information is according
to Orita et al. (2001), the crystal structure for CXCL8 was based on data
from Clore et al. (1990). (C) Crystal structure of the MIF homotrimer
(Orita et al., 2001), showing the barrel-shaped homotrimeric structure
and the inter-subunit interactions between two β-strands of one subunit
with β-sheets of adjacent subunits. Further stabilization is provided by
the hydrophobic interaction of Leu47 (pink) of the β3-strand of one
subunit with an adjacent hydrophobic pocket (green) on a second
subunit, comprising amino acids mainly positioned on the β2-strand. For
details, see text.
X-ray crystallography revealed human MIF as a trimer. The
barrel-shaped homotrimeric structure is stabilized by conserved
inter-subunit interactions between two β-strands of one subunit
with β-sheets of adjacent subunits (Sugimoto et al., 1996; Sun
et al., 1996a). Further stabilization is provided by the hydrophobic
interaction of Leu47 on the β3-strand of one subunit with an
adjacent hydrophobic pocket on a second subunit, comprising
amino acids mainly positioned on the β2-strand (El-Turk et al.,
2012) (Figure 1). However, X-ray and NMR structural analyses
are performed at mg/ml concentrations of the analyte, which
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are far off the physiological concentrations found in the cell or
in extracellular fluids. Overall, the physiological oligomerization
state of MIF remains elusive. Crosslinking studies revealed the
coexistence of MIF monomers, dimers, and trimers (Sugimoto
et al., 1996; Sun et al., 1996a,b), probably influenced by local
MIF concentrations. At physiological conditions, an equilibrium
of monomers and dimers has been described, whereas at concen-
trations >10µg/ml, trimeric or higher-ordered oligomers seem
to be preferred (Mischke et al., 1998; Calandra and Roger, 2003;
Philo et al., 2004; El-Turk et al., 2008). Interestingly, homotrimeric
MIF seems to drive inflammatory responses in the corneal epithe-
lium, as recently reported by Reidy et al. (2013). Nevertheless, it is
unlikely that the homotrimer is the only active form, as disruption
of the homotrimeric structure with the MIF inhibitor ebselen leads
to an increased chemotactic response (Ouertatani-Sakouhi et al.,
2010). In addition, concentration extrapolations into the physio-
logical ng/ml range would likely favor a predominant population
of the monomeric state. Yet, monomeric MIF is thought to be
intrinsically unstable, necessitating yet unknown mechanisms for
its stabilization (Bernhagen and Lue, unpublished observations).
To study the structure-activity relationship of MIF in the con-
text of its interaction with CXCR2, it appeared obvious to look for
homologous structural features with the cognate CXCR2 ligand
CXCL8, which, in its dimeric form, shares structural homology
with the MIF monomer (Figure 1). Bioinformatic prediction
analysis in conjunction with mutational studies revealed an impor-
tant receptor interacting motif in MIF that resembles the N-
terminal Glu-Leu-Arg (ELR) motif carried by a sub-group of CXC
chemokines, as shown for CXCL8. This MIF motif, consisting
of Asp45-X-Arg12, was termed “pseudo-(E)LR” motif, as the
glutamate (Glu/E) was substituted with an aspartic acid (Asp/D)
(Hebert et al., 1991; Weber et al., 2008). The non-adjacent residues
of this pseudo-(E)LR motif are located in neighboring loops of
the MIF protein with similar spacing as in the true ELR motif
(Figure 1). Site-directed mutagenesis studies showed an almost
complete inhibition of CXCR2 binding when the R12A or D45A
mutation was introduced into MIF. The MIF-R12A mutant also
exhibited a complete loss of chemotactic and arrest function.
Also, the MIF-D45A mutant showed a reduced chemotactic and
arrest activity in in vitro assays, whereas its hyperactivity towards
neutrophil recruitment in a peritonitis model was shown to be
CXCR4-mediated (Weber et al., 2008). Furthermore, evidence
became available for an interaction of the pseudo-(E)LR motif
with the extracellular loops EL-2 and EL-3 of CXCR2 (Kraemer
et al., 2011). Still, it should be noted that Arg12 and Asp45 of the
pseudo-(E)LR motif are located close to the critical Leu47 residue,
which is involved in inter-subunit hydrophobic interactions mod-
ulating the conformation and stability, but not the oligomerization
state, of homotrimeric MIF (El-Turk et al., 2012) (Figure 1). The
reduced leukocyte adhesion activity, which was observed for the
pseudo-(E)LR mutants (Weber et al., 2008), might thus not solely
result from changes in the direct MIF receptor interaction locus,
but could also result in part from modifications of the conforma-
tional stability of MIF by disturbance of the Leu47 region.
Interestingly, Kraemer et al. (2011) revealed the involvement
of an N-like loop in MIF in binding to CXCR2. This loop spans
10 amino acids from position 47 to 56 but is structurally different
Table 3 |The N-like loop of MIF shows only limited similarity with the
N-loop of CXC chemokines.
Chemokine N-loop sequence
CXCL1 LQTLQ GIHP
CXCL2 LQTLQ GIHL
CXCL3 LQTLQ GIHL
CXCL5 LQTTQ GVHP
CXCL6 LRVTL RVNP
CXCL7 IKTTS GIHP
CXCL8 IKTYSKPFHP
MIF LMAFGGSSEP
Adapted from Kraemer et al. (2011).
from the N-loop of CXC chemokines (Figure 1; Table 3). Whereas
the classical N-loop found in CXC chemokines contains 1–3 basic
residues and interacts with the N-terminus of the receptor, the
N-like loop of MIF has an acidic isoelectric point (pI) and inter-
acts with EL-1 and parts of EL-2 as well as with the N-terminus
of CXCR2, according to peptide spot array analysis. Importantly,
short MIF N-like loop-derived peptides blocked monocyte arrest
and inhibited MIF/CXCR2 interaction in a receptor competition
assay, verifying the importance of the N-like loop of MIF for
CXCR2 binding (Kraemer et al., 2011). Furthermore, amino acids
in the region between residues 50 and 68 are critical for obtain-
ing potent MIF neutralizing antibodies, which block important
biological activities such as cell proliferation and glucocorticoid
overriding in vitro and MIF-driven septic responses in vivo (Ker-
schbaumer et al., 2012). This confirmed that the N-like loop region
of MIF is critical for MIF-driven receptor-mediated processes.
Moreover, site-specific mutations of the cysteines at positions 57
and 60 and the use of peptides covering the region 50–65 fur-
ther underscored that the sequence region of the N-like loop, i.e.,
region 47–68, is critical for a variety of MIF activities (Kleemann
et al., 1998, 1999; Nguyen et al., 2003).
Taken together, as suggested by Kraemer et al. (2011), the
binding of MIF to CXCR2 seems to follow a two-site-binding
mechanism which is similar but not identical to that between
CXCL8 and CXCR2. In contrast, no structure-activity relation-
ship data are available yet for the interaction between MIF and
its receptors CD74 and CXCR4. Interesting questions are there-
fore, whether the uncovered motifs mediating the MIF/CXCR2
interaction are also important for the interaction between MIF
and CXCR4, whether for CD74 binding fully different regions are
required, and whether CXCR7, for which an interaction with MIF
has recently been implied, binds directly to MIF and utilizes the
N-like loop and pseudo-(E)LR motif as well.
Interestingly, the anti-inflammatory drug AV411 (Ibudilast)
and its analog AV1013, both allosteric inhibitors of MIF’s tau-
tomerase activity, were found to inhibit MIF-mediated CXCR2-
dependent chemotaxis of monocytes (Cho et al., 2010). AV1013
binds into a pocket formed by several C-terminal residues of
MIF. AV1013 binding apparently induces conformational changes
leading to both an inactivation of the tautomerase site and changes
at the MIF/CXCR2 interface, i.e., likely affecting the N-like loop
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or pseudo-(E)LR motif. Alternatively, conformational changes in
the tautomerase site could subsequently lead to conformational
changes in the receptor interaction interface of MIF (Cho et al.,
2010). Similarly, the hormonally inert isomer DT(4) of the thyroid
hormone thyroxine [T(4)], inhibited MIF’s tautomerase activity
by binding to a hydrophobic pocket harboring this enzymatic
function and reduced leukocyte accumulation in a carrageenan-
induced airpouch model in wildtype but not Mif−/− mice, pro-
viding further evidence for a potential participation of the tau-
tomerase site in MIF receptor-mediated chemotaxis (Al-Abed
et al., 2011). Yet, disruption of the MIF trimer, and therefore
of the active tautomerase site2, increased MIF-mediated chemo-
taxis (Ouertatani-Sakouhi et al., 2010). In addition, Fingerle-
Rowson et al. (2009) showed that the tautomerase-inactive mutant
P2G-MIF, which contains a mutation of the crucial catalytic N-
terminal Proline (Pro2)3, could still bind CD74 and mediate
growth regulation in a skin tumorigenesis model, although to a
somewhat reduced level. This indicates that the enzyme activity
per se is not essential for CD74 receptor binding. Also, in compar-
ison with wildtype MIF, the capacity of P2G-MIF to compete with
CXCL8 for binding to CXCR2-expressing cells was more reduced
than ligand competition in the CD74 binding assay (Fingerle-
Rowson et al., 2009). This suggests that the Pro2 residue and/or
conformational changes in the tautomerase site affect MIF binding
to CXCR2 more than the MIF-CD74 interaction.
MIF’S ARREST FUNCTION THROUGH ITS RECEPTOR CXCR2
MIF, immobilized on the endothelial surface, triggers the arrest of
monocytes/neutrophils and T-cells through CXCR2 and CXCR4,
respectively, by a rapid and transient activation of the leukocyte
integrins LFA1 and VLA4 (Box 3) (Bernhagen et al., 2007). While
the precise mechanism of MIF deposition on ECs has not yet been
explored, the basic pI could be a likely explanation. Alternatively,
ECs express CD74 which has been found to be modified by chon-
droitin sulfate, thus providing a possible anchoring site for MIF
as well.
For immobilized classical chemokines, the GPCR/Gαi-
mediated intracellular signaling cascade in leukocytes triggering
integrin activation and leukocytic arrest, has been shown to be
very complex, with currently 65 proteins identified to be pos-
sibly involved (Ley et al., 2007; Montresor et al., 2012). Three
main stages of integrin activation are distinguished. These involve:
(1) phospholipase C (PLC)-mediated calcium influx, (2) small
GTPases, and (3) actin-binding proteins as talin-1 and kindlin-
3, as described in more detail elsewhere (Ley et al., 2007; Lefort
and Ley, 2012; Montresor et al., 2012) (Figure 2). However, this
model of GPCR-mediated integrin activation cannot be univer-
sally applied to all conditions, and it is expected to be dependent
on the GPCR, GPCR ligand, the integrin activated, and the bio-
logical context (Ley et al., 2007; Montresor et al., 2012). For
2MIF tautomerase activity requires trimerization.
3In the paper by Fingerle-Rowson et al. (2009), MIF sequence numbering refers to
the processed MIF protein after Met1 removal. Thus, the protein sequence of MIF
in that paper starts with Pro1 rather than Pro2, the latter referring to the cDNA
sequence. In the current article, we prefer to refer to this proline residue as Pro2, i.e.,
applying the numbering according to the cDNA sequence to be consistent with the
sequence numbering of the mutants above.
MIF/CXCR2, few details are known about the exact molecular
delineation of proteins involved in MIF receptor-mediated inte-
grin activation. Initial inhibitor studies revealed MIF to mediate
monocyte and T-cell adhesion by Gαi proteins and PI3K (Bern-
hagen et al., 2007), a kinase which is directly activated by the Gβγ
dimer and which mediates adhesion stabilization of neutrophils
to CXCL1 through CXCR2 (Smith et al., 2006). Also, MIF trig-
gered CXCR2-dependent calcium transients. In mouse fibroblasts,
recombinant MIF induces the activation of RhoA GTPase and Rho
kinase, and Mif-deficient fibroblasts showed a reduction in RhoA
GTPase activation and stress fiber formation (Swant et al., 2005).
Of note, the latter has been linked with integrin clustering (Roovers
and Assoian, 2003). Also VASP, LASP-1, IQGAP1, and NHERF1
were recently identified to interact with CXCR2 and to be involved
in CXCL8-triggered chemotaxis (Neel et al., 2009, 2011; Wu et al.,
2012), but it remains unknown whether this is directly linked to
integrin activation, or whether these proteins are also involved in
MIF/CXCR2-mediated arrest.
In addition to this direct link of MIF-CXCR2 signaling towards
integrin activation, MIF has been shown to induce the migration
of human chondrosarcoma cells by upregulating the transcrip-
tion of the αvβ3 integrin through PI3K/AKT/NF-κB signaling in a
CXCR2- and CXCR4-mediated way (Lee et al., 2012). This again
indicates MIF’s potential to mediate chemokine-like functions
through indirect effects, by regulating the expression of proteins
involved in leukocyte adhesion, as discussed previously.
CD74 AND CXCR4 AS ALTERNATIVE MIF RECEPTORS
CD74
In 2003, the CD74 protein was discovered as a high affinity recep-
tor for MIF (Leng et al., 2003). CD74 is well-known as an MHC
class II chaperone, as it is the membrane-expressed portion of the
invariant chain (II), which typically regulates antigenic peptide
loading to MHC class II proteins through its CLIP domain. How-
ever, CD74 can also be expressed in the absence of the MHC class II
protein, thus executing functions as membrane receptor (Borghese
and Clanchy, 2011). The CD74 receptor is a type II membrane-
spanning protein with a short cytoplasmic N-terminus. As a result,
accessory signaling molecules like Src, CD44, c-Met, or other co-
receptors are necessary to mediate CD74 signaling by MIF, i.e., by
forming a functional receptor-tyrosine-kinase-(RTK)-like com-
plex (Bernhagen et al., 2007; Gordin et al., 2010). Signaling of
MIF through CD74 has been linked with MIF’s pro-inflammatory
and anti-apoptotic functions. For instance, interaction of MIF
with CD74 leads to the activation of MAPKs and other protein
kinases. One example is the sustained and transient activation of
the MAPK ERK1 and ERK2 (Lue et al., 2006; Shi et al., 2006).
Sustained ERK activation is mediated by CD74/CD44 and protein
kinase A and has been linked to cell proliferation and enhanced
pro-inflammatory phospholipase A2 activity (Mitchell et al., 1999;
Lue et al., 2006; Shi et al., 2006). Recently, also β-arrestin-1 was
shown to be involved in MIF-triggered sustained ERK activation,
mediating MIF internalization in a CD74- and clathrin-dependent
manner (Xie et al., 2011). Another example is the effect of MIF
and CD74 on the MAPK Jun N-terminal kinase (JNK). MIF either
impedes JNK signaling and JNK-mediated apoptosis, or rapidly
initiates JNK activation through CXCR4/CD74, activating the
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FIGURE 2 | Signaling by exogenous MIF. MIF can induce signaling
cascades through its receptors CD74, CXCR2, and CXCR4. These
pathways underlie MIF’s biological functions, e.g., leukocytic integrin
activation, cell proliferation, and anti-apoptosis, induction of
pro-inflammatory gene expression. The detailed molecular mechanism
underlying MIF’s arrest function through its receptors CXCR2 and CXCR4
is still unexplored. Three main steps in GPCR-mediated integrin activation
can be distinguished, i.e., PLC-mediated calcium mobilization, activation of
small GTPases and recruitment of actin-binding proteins linking the
integrin to the actin cytoskeleton. PIP2, phosphatidylinosytol
4,5-biphosphate; PLC, phospholipase C; IP3, inosytol 1,4,5-triphosphate;
DAG, diacylglycerol; Ca2+, calcium; ER, endoplasmic reticulum; GDP,
guanosine diphosphate; GTP, guanosine triphosphate; guanine nucleotide
exchange factor; PLA2, phospholipase A2; ERK, extracellular signal-related
kinase; PI3K, phosphatidylinositol 3-kinase; NF-κB, nuclear factor-κB; BAD,
BCL2-associated agonist of cell death; FOXO3A, forkhead box O3a;
COX-2, cytochrome C oxidase subunit 2; JNK, c-Jun N-terminal kinase;
AP1 (c-Jun), activator protein-1.
Src/PI3K/JNK/AP1 pathway, which results in the expression of the
pro-inflammatory protein CXCL8 (Kleemann et al., 2000; Qi et al.,
2009; Lue et al., 2011). Also, MIF-CD74 signaling has been shown
to promote B-cell survival through CD44/PI3K/AKT-mediated
NF-κB activation and NF-κB-induced CXCL8 secretion (Binsky
et al., 2007; Gore et al., 2008). Furthermore, a CD74/Src/PI3K/AKT
pathway links MIF to the phosphorylation of the pro-apoptotic
proteins BAD and FOXO3a, providing a survival signal (Lue et al.,
2007). Also, cyclooxygenase (COX)-2, which prevents the accumu-
lation of p53, can be upregulated through this pathway, likewise
contributing to survival (Mitchell et al., 2002).
In addition, CD74 has been shown to be involved in MIF-
mediated leukocyte chemotaxis and arrest, although not in all
circumstances. The administration of a CD74 blocking antibody
reduced the MIF-dependent monocyte arrest on ex vivo carotid
arteries from atherosclerotic mice (Bernhagen et al., 2007), and
activation of macrophage CD74 by MIF leads to an ERK1/2-
dependent release of Cxcl1 and Cxcl2, mediating the MIF-induced
accumulation of neutrophils in the alveolar space (Takahashi
et al., 2009). Furthermore, Ccl2-triggered monocyte arrest and
endothelial transmigration were severely decreased in Mif- and
Cd74-deficient mice. Mif- and Cd74-deficient macrophages also
showed a reduced Ccl2-triggered chemotaxis in vitro, which was
associated with a reduced Rho GTPase and Mapk activation.
However, Mif-deficient macrophages showed a lower expression
of the α4 integrin and of the Mapk-regulating protein Mkp1,
which was not the case for Cd74-deficient macrophages, sug-
gesting that the involvement of endogenous Mif and Cd74 in
Ccl2-induced monocyte recruitment or adhesion could at least
partially be mediated through distinct mechanisms. Further-
more, exogenous MIF could restore deficient Ccl2-triggered leuko-
cyte adhesion, but not endothelial transmigration, in Mif−/−
and Cd74−/− mice to the same extent, indicating that exoge-
nous MIF enhances CCL2-mediated leukocyte adhesion mostly
independently of CD74. In contrast, exogenous MIF-induced
leukocyte adhesion and transmigration were severely impaired
in Cd74−/− mice (Fan et al., 2011), suggesting an alterna-
tive mechanism underlying MIF- versus CCL2/MIF-induced
leukocyte adhesion in vivo. Alternatively, these different obser-
vations could result from differentially targeting vascular versus
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leukocytic cells to a different degree, when examining MIF-
induced versus CCL2/MIF-induced leukocyte adhesion, respec-
tively. Of note, MIF also desensitized CCL2-mediated chemo-
taxis (Hermanowski-Vosatka et al., 1999), implying a MIF/CXCR-
mediated cross-signaling mechanism as known for classical
chemokines.
CXCR4
Another chemokine receptor known to interact with MIF is
CXCR4, as shown by Bernhagen et al. (2007). Prior to this find-
ing, the CXCL12/CXCR4 interaction was thought to be highly
specific, from the receptor as well as from the ligand site (Mur-
phy et al., 2000). The MIF/CXCR4 interaction together with the
identification of the CXCL11 receptor CXCR7 as an additional
receptor for CXCL12 (Balabanian et al., 2005; Burns et al., 2006;
Thelen and Thelen, 2008), disproved the existence of a non-
promiscuous interaction. In fact, CXCR4 is also known to interact
with the HIV gp120 protein and a recent report suggests that
serum ubiquitin also interacts with CXCR4 (Saini et al., 2010).
CXCR4 is widely expressed, particularly on many cell types of
the immune system (Murphy et al., 2000) (Table 4). The knock-
out of Cxcr4 in mice is embryonically lethal, due to defects in
hematopoiesis, vasculo-, cardio-, and neurogenesis (Ma et al.,
1998; Zou et al., 1998). CXCR4 has prominently been implicated
in cell recruitment processes, with CXCL12 mediating the recruit-
ment of hematopoietic and vascular progenitor cells from the bone
marrow (Mohle et al., 1998; Sainz and Sata, 2007). On the other
hand, MIF has been shown to induce T-cell recruitment and arrest
through CXCR4-induced, rapid α4β1 (VLA4) integrin activation
(Bernhagen et al., 2007). MIF was also identified as the critical
autocrine CXCR4 ligand driving cell invasion by drug-resistant
colon carcinoma HT-29 cells (Vera et al., 2008; Dessein et al.,
2010). Little is known about the molecular details of MIF/CXCR4
signaling. In T-cells, MIF stimulation increases CXCL8 expression
through both CXCR4 and CD74, depending on Src, PI3K, and
JNK phosphorylation (Lue et al., 2011). Earlier on, CXCR4/CD74
heterodimers were found in monocytes, T-cells and fibroblasts,
and MIF-induced AKT signaling was shown to be reduced both by
blocking CD74 and CXCR4, indicating a functional CXCR4/CD74
MIF receptor complex (Schwartz et al., 2009).
CXCR7
Tarnowski et al. (2010) implicated a recently identified chemokine
decoy receptor in MIF internalization and MIF-dependent adhe-
sion of rhabdomyosarcoma cells. This seven-transmembrane-
receptor, encoded by the RDC-1 gene, was named CXCR7 and
characterized as a receptor for CXCL11 and CXCL12 (Balabanian
et al., 2005; Burns et al., 2006). CXCR7 is expressed on a vari-
ety of cells, including leukocytes, activated ECs, mature neurons,
CD34+ progenitor cells, and several tumor cell lines (Balabanian
et al., 2005; Burns et al., 2006; Infantino et al., 2006; Zabel et al.,
2009; Hattermann et al., 2010; Tarnowski et al., 2010; Shimizu
et al., 2011). Unlike the prototypical chemokine receptors, CXCR7
carries two amino acid substitutions in the DRYLAIV motif (A/S
and V/T) on the second intracellular loop, resulting in a change
in the adaptor motif for G proteins and thus to a loss of G pro-
tein signaling (Zabel et al., 2009). Even though typical chemokine
receptor signaling pathways, like calcium mobilization, are absent
Table 4 | MIF receptor expression in cell types relevant in atherogenesis.
Cell type Receptor Remark Reference
Monocytes/macrophages CXCR2 Murphy et al. (2000)
CXCR4 Murphy et al. (2000), Sunderkotter et al. (2004),
Ingersoll et al. (2010)
CD74 Martin-Ventura et al. (2009)
Neutrophils CXCR2 Murphy et al. (2000)
CXCR4 Upon stimulation Bruhl et al. (2003)
No CD74
T-cells CXCR4 Murphy et al. (2000)
CXCR2 On some CD8+ T-cells, not on CD4+ T-cells Chuntharapai et al. (1994)
CD74 On a subset of activated T-cells Stein et al. (2007)
B-cells No CXCR2 Chuntharapai et al. (1994)
CXCR4 Nie et al. (2004)
CD74 Gore et al. (2008)
ECs CXCR2 Murdoch et al. (1999)
CXCR4 Gupta et al. (1998)
CD74 Only upregulated under inflammatory stimulation Stein et al. (2007)
SMCs CXCR2 Govindaraju et al. (2006)
CXCR4 Schecter et al. (2001)
CD74 In atherosclerotic plaques Martin-Ventura et al. (2009)
ECs, endothelial cells; SMCs, smooth muscle cells.
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for CXCR7, other signaling cascades have been described. For
example, the β-arrestin-dependent internalization of chemokines
by CXCR7 results in the activation of MAPK signaling and the
CXCL12/CXCR7 interaction promotes Gαi-independent ERK and
AKT phosphorylation, mediating T-cell chemotaxis and survival
(Balabanian et al., 2005; Rajagopal et al., 2010; Kumar et al.,
2012), although these findings have been controversial in part.
On the other hand, CXCL11 binding to CXCR7 inhibits the
CXCL12/CXCR4-mediated transendothelial migration of breast
cancer cells (Dambly-Chaudiere et al., 2007; Boldajipour et al.,
2008; Zabel et al., 2009). Thus, CXCR7 might play a role in
MIF-mediated chemotaxis by generating MIF gradients leading to
differential signaling, act as a co-receptor or influence chemokine
crosstalk. Whether CXCR7 is implicated in a direct interaction
with MIF or whether the observed effects by Tarnowski et al.
(2010) are based on an indirect interaction, for instance by form-
ing a functional complex with CXCR4 as identified by Luker
et al. (2009), will have to be elucidated in the future. Never-
theless, the interaction of MIF with CXCR7 might be a further
fine-tuning mechanism in the complex chemokine/chemokine
receptor system.
RECEPTOR OLIGOMERIZATION
Receptor oligomerization is a further possibility to modulate
ligand affinity, ligand internalization and signal transduction with
an impact on cellular processes like cell arrest or cell activation. It
is well established that chemokine receptors form dimers or even
higher-order oligomers (Milligan, 2007; Thelen et al., 2010; Krae-
mer et al., 2013). Also, the MIF receptors CXCR2 and CXCR4 have
been shown to homodimerize and even multimerize in a ligand-
independent manner (Trettel et al., 2003; Hamatake et al., 2009;Wu
et al., 2010). Moreover, CXCR2 and CXCR4 heterodimerize with
various CXC receptors. For example, the MIF receptors CXCR4
and CXCR7 form a complex, thus modulating CXCL12-mediated
CXCR4-dependent chemotaxis (Thelen and Thelen, 2008; Levoye
et al., 2009). Also, CXCR2 heterodimerizes with CXCR1 (Wilson
et al., 2005). Heterocomplex formation is not solely restricted to
receptors of the same sub-family, but also exists between different
chemokine receptor subtypes (Kraemer et al., 2013). The cooper-
ation of the CXCR4 and CCR5 receptor, for example, is required
for chemokine-induced T-cell stimulation at the immunological
synapse (Contento et al., 2008). Furthermore, complexes between
chemokine receptors and other receptor types were observed. As
such, CXCR4 engages with the dopamine receptor and for CXCR2,
a complex with the δ-opiod receptor (DOP) was demonstrated
(Parenty et al., 2008; Kraemer et al., 2013). Interestingly, the CD74
receptor interacts with both CXCR2 and CXCR4 (Bernhagen et al.,
2007; Schwartz et al., 2009). CXCR2/CD74 heterodimers are impli-
cated in leukocyte recruitment. In this context, it was suggested
that CD74 amplifies MIF/CXCR2-mediated signaling, as neu-
trophils, which lack CD74, only show a weak migratory response
to MIF, whereas HL-60 cells, which do not express detectable levels
of CD74, increasingly migrate to MIF after ectopic CD74 expres-
sion (Bernhagen et al., 2007). CXCR4/CD74 heterodimers were
found in monocytes, T-cells, and fibroblasts. Both CXCR4 and
CD74 mediate MIF-induced AKT signaling and a fast and transient
activation of the JNK/AP1 pathway, suggesting the existence of a
functional heterocomplex (Schwartz et al., 2009; Lue et al., 2011).
Taken together, MIF/CXCR interactions play a role in inflamma-
tion and inflammatory leukocyte recruitment and arrest. The pos-
sibility that MIF interacts not only with a single receptor, but with a
complex of receptors could further add to a highly controlled cell-,
site- and disease-stage specific inflammatory cell adhesion process.
MIF IN ATHEROSCLEROSIS
Atherosclerosis is caused and sustained by inflammatory processes
in the vessel wall. The deposition and oxidation of low density
lipoprotein (LDL) in the intima drives EC and SMC activation, and
the recruitment and infiltration of leukocytes (Weber and Noels,
2011). Whereas MIF is only detectable at low levels in healthy
vessels, hyperlipidemia strongly enhances MIF expression in ECs,
SMCs, monocytes, and T-cells in atherosclerotic lesions (Lin et al.,
2000; Burger-Kentischer et al., 2002, 2006), and an even further
upregulation during atheroprogression suggested a role for MIF
in plaque destabilization (Burger-Kentischer et al., 2002) (Table 5).
In vitro, leukocytes and vascular cells have been shown to express
MIF upon several inflammatory triggers (Table 2). Typically, an
initial secretion pulse of preformed MIF protein precedes MIF
transcription (Simons et al., 2011). Also, all cell types involved
in atherogenesis, including monocytes/macrophages, neutrophils,
B- and T-lymphocytes, ECs, and SMCs, express at least one of the
MIF receptors CD74, CXCR2, or CXCR4 (Table 4), suggesting that
they do not solely act as MIF storage pools, but also respond to
secreted MIF.
Of note, functional animal studies confirmed an atheroprogres-
sive role of MIF, showing a reduced lesion size and inflammatory
profile in Mif-deficient mice, or after treatment with a Mif block-
ing antibody (Table 5) (Pan et al., 2004; Burger-Kentischer et al.,
2006; Bernhagen et al., 2007; Verschuren et al., 2009). Remarkably,
Mif blockade even induced a regression of established atheroscle-
rotic lesions (Bernhagen et al., 2007). Similarly, Mif neutralization
reduced injury-induced restenosis, in which Mif expression is ini-
tially upregulated in SMCs, and in ECs and foam cells in a later
stage (Chen et al., 2004; Schober et al., 2004).
These atheroprogressive effects of MIF can be linked with MIF’s
potential to trigger the expression of inflammatory mediators
and mediate leukocyte recruitment and arrest directly or through
the induction of adhesion molecules and chemokines in ECs
and monocytes/macrophages (Figure 3) (Bernhagen et al., 1994;
Calandra et al., 1994, 1995; Lan et al., 1997; Lin et al., 2000; Amin
et al., 2006; Gregory et al., 2006, 2009; Takahashi et al., 2009; Cheng
et al., 2010). Furthermore, the ability of MIF to stimulate oxidized
LDL (oxLDL) uptake by macrophages (Atsumi et al., 2000), and
its association with protease expression and a reduced PDGF-
BB-induced SMC migration (Pan et al., 2004; Schrans-Stassen
et al., 2005; Verschuren et al., 2005) may further contribute to
MIF’s plaque destabilizing properties in hyperlipidemia-induced
atherogenesis. In the context of injury-induced neointima forma-
tion, interference with MIF’s anti-apoptotic effect could underlie
the enhanced apoptosis in conditions of Mif antibody treatment
(Mitchell et al., 2002; Chen et al., 2004), whereas a report on MIF
driving SMC proliferation could be linked to a decreased medial
cell proliferation under conditions of MIF blockade (Chen et al.,
2004).
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Table 5 | MIF in atherosclerosis.
Reference
MIF EXPRESSION IN ATHEROSCLEROSIS AND RESTENOSIS
Native or diet-induced atherosclerosis
Rabbit Upregulated in macrohages, ECs, and SMCs from early atherosclerotic lesions Lin et al. (2000)
Apoe−/− mouse Enhanced in all cell types (monocytes, T-cells, ECs, SMCs), but mostly in monocytes Burger-Kentischer et al. (2006)
Human Enhanced in all cell types (monocytes, T-cells, ECs, SMCs) Burger-Kentischer et al. (2002)
Further upregulated upon progression
Injury-induced restenosis
Apoe−/−- ; Ldlr−/− Upregulated in medial SMCs (early) and ECs and foam cells (late) Chen et al. (2004), Schober et al. (2004)
EFFECTS OF MIF BLOCKADE ON ATHEROSCLEROSIS IN MICE
Native or diet-induced atherosclerosis
Mif−/−; Ldlr−/− High-fat diet Smaller and less progressed lesions Pan et al. (2004)
Reduced cell proliferation
Reduced cathepsin expression
Mif−/−; Ldlr−/− Chow diet Reduced lesion size Verschuren et al. (2009)
Reduced macrophage content
Apoe−/−
+Mif blocking Ab
Chow diet Only non-significant reduction in aortic lesion size Burger-Kentischer et al. (2006)
Reduced macrophage content
Reduced aortic expression of pro-inflammatory
markers (CD40L,TNFα, IL12, ICAM1), the transcription
regulators C-EBPβ and phospho-cJun, and of MMP2
Atherosclerotic
Apoe−/− +Mif
blocking Ab
High-fat diet Regression in established lesions Bernhagen et al. (2007)
Reduced macrophage and T-cell content
Injury-induced restenosis
Ldlr−/−
+Mif blocking Ab
Experimental
angioplasty
Reduced neointimal size Chen et al. (2004)
Reduced leukocyte recruitment
Reduced cell proliferation in media and neointima
Increased apoptosis in media and neointima
Apoe−/−
+Mif blocking Ab
Wire injury No significant effect on neointimal size Schober et al. (2004)
Reduced macrophage content
Increased SMC and collagen content
HUMAN EPIDEMIOLOGICAL STUDIES
MIF SNP rs755622 (-173 CC genotype) risk factor for CHD and diverse inflammatory diseases Donn et al. (2001), Herder et al. (2008)
Although not confirmed by all studies Palomino-Morales et al. (2010)
MIF-173 CC genotype more frequent in Turkish children with cardiomyopathy Col-Araz et al. (2012)
MIF SNP rs1007888 (GG genotype) associated with enhanced MI risk in female Czech patients Tereshchenko et al. (2009)
Enhanced MIF plasma levels predictive for enhanced heart failure in CHD patients with impaired
glucose tolerance or type 2 diabetes mellitus
Makino et al. (2010)
Increased MIF plasma levels in patients with ACS, associated with inflammatory marker expression
(CRP, IL6)
Muller et al. (2012)
INFLAMMATORY/CARDIOVASCULAR EFFECTS OF MIF
Monocytes/macrophages
Enhances direct monocyte recruitment and arrest through CXCR2 Bernhagen et al. (2007)
Enhances CCL2-induced monocyte recruitment Fan et al. (2011)
Enhances oxLDL uptake and degradation Atsumi et al. (2000)
(Continued)
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Table 5 | Continued
Reference
Induces inflammatory mediators TNFα, IL1β, IL6, IL8 Bernhagen et al. (1994), Calandra et al.
(1994, 1995), Lan et al. (1997)
NO, iNOS Bernhagen et al. (1994), Lan et al. (1997)
Enhances expression of chemokines and adhesion molecules Amin et al. (2006), Takahashi et al. (2009)
Interferes with p53-mediated apoptosis Mitchell et al. (2002)
T-cells
Enhances direct T-cell recruitment and arrest through CXCR2 Bernhagen et al. (2007)
SMCs
Mif−/− SMCs: reduced cathepsin expression, reduced elastin/collagen degradation capacity Pan et al. (2004)
Inhibits long-term PDGF-BB-induced SMC migration, despite short-term stimulatory effect Schrans-Stassen et al. (2005)
Drives SMC proliferation in some studies (but not all) Chen et al. (2004), Schrans-Stassen et al.
(2005)
ECs
Enhances the (cytokine-induced) expression of chemokines and adhesion molecules Lin et al. (2000), Gregory et al. (2006,
2009), Cheng et al. (2010)
Other
Colocalizes with MMP1/9 in human vulnerable plaques Kong et al. (2005a,b)
Pro-angiogenic Chesney et al. (1999), Ogawa et al.
(2000); Amin et al. (2003)
Apoe, apolipoprotein E; Ldlr, low density lipoprotein receptor; ECs, endothelial cells; SMCs, smooth muscle cells; Ab, antibody; TNF, tumor necrosis factor; IL, inter-
leukin; ICAM, intercellular adhesion molecule; MMP, matrix metalloproteinase; CEBP, CCAAT/enhancer binding protein; SNP, single nucleotide polymorphism; CHD,
coronary heart disease; MI, myocardial infarction; ACS, acute coronary syndrome; CRP, C-reactive protein; oxLDL, oxidized low density lipoprotein; NO, nitrix oxide;
iNOS, inducible nitric oxide synthase; PDGF, platelet-derived growth factor.
Importantly, human epidemiological studies support a pro-
atherogenic role of MIF (Table 5). These studies showed a single
nucleotide polymorphism (SNP) in the MIF promotor (MIF-173
CC genotype) to be a risk factor for coronary heart disease (CHD)
(Herder et al., 2008) and to be more frequent in Turkish children
with cardiomyopathy (Col-Araz et al., 2012). SNP rs1007888 (GG
genotype) was associated with enhanced risk of myocardial infarc-
tion in female Czech patients (Tereshchenko et al., 2009). Further-
more, increased plasma levels of MIF were identified as a risk factor
for increased heart failure in CHD patients with impaired glucose
tolerance or type 2 diabetes mellitus (Makino et al., 2010), and
were associated with inflammatory marker expression in patients
with acute coronary syndrome (ACS) (Muller et al., 2012).
In conclusion, multiple animal and human studies support
MIF’s pro-atherosclerotic and pro-inflammatory role, and reveal
MIF as an interesting target for drug development. The list
of MIF inhibitors is steadily growing and includes small molecular
weight or peptide drugs targeting mostly MIF’s catalytic pocket or
MIF trimerization (Garai and Lorand, 2009; Ouertatani-Sakouhi
et al., 2010). An interesting therapeutic strategy would be to inter-
fere with the CLF functions of MIF by blocking the interaction
of MIF with its receptors. CXCR2 and CXCR4 inhibitors have
recently been discussed in more detail (Liang, 2008; Stadtmann
and Zarbock, 2012). However, an attractive alternative is a direct
targeting of MIF instead of its receptors or devising strategies that
would specifically target the MIF/CXCR interface but not other
CXCR2- or CXCR4-mediated signaling effects, i.e., as stimulated
by the cognate ligands CXCL8 or CXCL12, respectively. In the
context of atherosclerosis, interference with MIF binding to both
CXCR2 and CXCR4 by using a MIF blocking antibody interfered
with MIF’s pro-atherosclerotic functions (Bernhagen et al., 2007),
while it would leave the protective homeostatic functions of the
CXCL12-CXCR4 axis preserved (Koenen and Weber, 2010). Spe-
cific targeting of binding motifs in MIF, e.g., the pseudo-(E)LR
and the N-like loop motifs critical for the MIF-CXCR2 inter-
action, provides an interesting strategy, but MIF motifs crucial
for MIF-CXCR4 binding still remain to be identified. Finally,
it is important to keep in mind that MIF exerts pleiotropic
functions, and also behaves protective in different settings. For
example, the MIF-CD74 axis is cardioprotective after myocardial
ischemia/reperfusion injury (Miller et al., 2008; Qi et al., 2009;
Luedike et al., 2012), and also exerts an important antifibrotic
effect in experimental liver fibrosis (Heinrichs et al., 2011). Also,
MIF polymorphisms associated with higher MIF expression were
found to have a beneficial effect in community-acquired pneumo-
nia (Yende et al., 2009). Therefore, possible negative side effects
should always be carefully monitored for each new MIF inhibitor.
PERICYTES COORDINATE INTERSTITIAL LEUKOCYTE
MIGRATION THROUGH MIF
MIF plays a pivotal role in leukocyte chemotaxis in the blood and
other body fluids, in the arrest of leukocytes on the endothelium
and their transmigration into the sub-endothelial space (Gregory
et al., 2006; Bernhagen et al., 2007; Cheng et al., 2010; Santos et al.,
www.frontiersin.org May 2013 | Volume 4 | Article 115 | 13
Tillmann et al. Arrest functions of MIF in atherogenesis
FIGURE 3 | Role of MIF in atherogenesis. MIF is secreted upon
atherogenic stimulation of ECs, SMCs, and leukocytes. Once released,
MIF activates leukocyte integrins, upregulates the expression of adhesion
molecules and other chemokines, together mediating leukocyte
recruitment and arrest on the endothelium. MIF is also implicated in
pro-inflammatory cytokine expression, transdifferrentiation of
macrophages to foam cells, MMP and cathepsin induction in SMCs, and
regulation of SMC proliferation and migration. A potential role for MIF in
neovascularization in advanced plaques remains to be investigated. For
more details, see text.
2011). Intriguingly, it was recently shown that MIF also plays a
role in directing extravasated leukocytes in the peri-endothelial
compartment to NG2+ pericyte-rich regions along arterioles and
capillaries (Stark et al., 2013) (Box 4). Stark et al. (2013) identi-
fied NG2+ pericytes as the main source of MIF in the perivascular
compartment of microvessels and demonstrated that stimulation
of these cells with pro-inflammatory stimuli such as TNF, LPS, or
damage-associated molecular patterns (DAMPs) released MIF and
immobilized it on the cell surface of pericytes, probably through
binding to CD74 and/or CXCR4. Furthermore, the release of MIF,
CCL2, and CXCL8, together with the expression of ICAM1 on the
pericyte surface mediated monocyte and neutrophil chemotaxis in
an LFA1- and MAC1-dependent manner. As leukocyte extravasa-
tion occurs only in the postcapillary venules, which are covered
by NG2− pericytes, but not in arterioles and capillaries con-
taining NG2+ pericytes, neutrophil and macrophage interaction
with NG2+ pericytes can only occur after successful interstitial
migration from their entry point in postcapillary venules toward
capillary and arteriolar pericytes, providing interstitial migration
routes for the extravasated leukocytes (Murfee et al., 2005; Stark
et al., 2013). The importance of MIF in this leukocyte migration
track in the pericyte sheath was stressed by the observation that
subcutaneous injection of the MIF inhibitor ISO-1 in mice reduced
the number of accumulated neutrophils around NG2+ pericytes
in the skin microvasculature without affecting their extravasation
(Stark et al., 2013). This finding, together with the capacity of
MIF to induce CCL2-dependent leukocyte extravasation in post-
capillary venules (Gregory et al., 2006), supports the concept,
that the gradual interplay of MIF with different cell types, other
chemokines, or inflammatory mediators is important for success-
ful MIF-mediated leukocyte direction from the blood vessel lumen
to the site of inflammation.
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Box 4 Pericytes.
Pericytes are also known as mural or rouget cells. They are essential components of microvessels, in which they are closely associated
with the microvessel ECs, enveloped in a common basement membrane. Pericytes adhere to matrix proteins like fibrinogen, laminin, and
collagen of the basement membrane through integrins. Due to their morphological and phenotypical heterogeneity, it is hard to distinguish
them from other peri-endothelial cells, causing them to be often mixed up with vascular SMCs or mesenchymal cells. Also, no specific
marker has been found yet. For example, pericytes covering postcapillary venules are NG2− αSMA+, whereas pericytes on arterioles and
capillaries are NG2+. Some commonly used markers are α-smooth muscle actin (αSMA), alanyl(membrane)aminopeptidase (CD13), chon-
droitin sulfate proteoglycan 4 (NG2), melanoma cell adhesion molecule (CD146), platelet-derived growth factor receptor (PDGFR)-β, and
desmin.
CONCLUDING REMARKS
MIF has been recognized as an important CLF chemokine medi-
ating leukocyte recruitment and arrest in the context of many
inflammatory diseases, in particular atherosclerosis. The recep-
tors CD74, CXCR2, and CXCR4 have been identified to bind
MIF and to mediate MIF-triggered arrest functions, but the mol-
ecular mechanisms underlying MIF-mediated receptor signal-
ing toward different cellular functions still need further refine-
ment. For example, the molecular sequelae of MIF-triggered
events leading to integrin activation on leukocytes is still largely
unexplored. In addition, the composition, balance, and differ-
ential functionality of different MIF receptor complexes needs
further investigation. Identification and refinement of the crit-
ical receptor binding sites of MIF could stimulate the search
for drugs that specifically interfere with MIF binding to only
one or a certain selection of MIF receptors, with the aim to
selectively interfere with only a subset of MIF’s pleiotropic
functions.
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